| Request a sample from "The Infoshop", another service of Global Information.
|
SUMMARY
Introduction
- The osteoporosis market has grown near% per year sin00, presenting many
- opportunities for drug manufacturers. However, several effective,
well-established, and
- reasonably priced agents dominate the market. Even novel therapies
satisfying a distinct need
- face tremendous challenges when launched in this competitive arena.
Get the Answers You Need to Shape Your Strategy
Eli Lilly's bone-building drug Forteo (teriparatide) was a promising
breakthrough treatment for osteoporosis that achieved disappointing sales and
relatively low acceptance among patients and physicians. Why did Forteo fail
to meet early expectations for its use? Several issues during Forteo's
development phase greatly affected its launch and initial uptake. What are
some problems that can hinder the uptake of a breakthrough therapy? What
lessons can be learned from Forteo's development and launch? Even an effective
novel agent may face challenges when placed in a market that is saturated with
well-established therapies. What factors must drug developers consider when
developing and launching new agents?
Scope
- Overview of osteoporosis: disease description, prevalence, and
economic burden.
- Current market for osteoporosis therapies: overview of common
agents used to treat osteoporosis.
- Case study of Forteo: development and approval, launch and early
performance, outlook, lessons to be learned.
TABLE OF CONTENTS
- Executive Summary
- Strategic Considerations
- Stakeholder Implications
- Introduction
- An Overview of Osteoporosis
- Disease Description, Prevalence, and Economic Burden
- Current Treatments
- Bisphosphonates
- SERMs
- Osteoporosis Mark5
- Case Study: Forteo
- Forteo's Development and Approval
- Forteo's Launch and Early Performance
- The Outlook for Forteo
- What Can Be Learned from Forteo?
Tables
- 1. Leading Therapies for the Treatment of Osteoporosis
- 2. Factors Limiting the Use of Forteo
Figures
- 1. Diagram of Bone Remodeling
- 2. Targets for Current Drugs in the Bone Remodeling Process
- 3. Market Share of Leading Drug Classe05
- 4. Quarterly Sales of Forte6
|
